These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20485319)

  • 1. FDA LABA warning: is there anything new here?
    Weiss ST
    Clin Pharmacol Ther; 2010 Jun; 87(6):638-9. PubMed ID: 20485319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's recommendations on the use of long-acting {beta}2 agonists in the management of asthma.
    Robinson CA
    Ann Pharmacother; 2010 Oct; 44(10):1651-4. PubMed ID: 20841520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FDA and safe use of long-acting beta-agonists in the treatment of asthma.
    Chowdhury BA; Dal Pan G
    N Engl J Med; 2010 Apr; 362(13):1169-71. PubMed ID: 20181964
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values.
    Kramer JM
    N Engl J Med; 2009 Apr; 360(16):1592-5. PubMed ID: 19369665
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA imposes new rules for long-acting asthma drugs. Recent studies show that long-term use of LABAs alone may make asthma symptoms worse, not better.
    Duke Med Health News; 2010 May; 16(5):7. PubMed ID: 20518134
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-2 adrenergic agonists: focus on safety and benefits versus risks.
    Ortega VE; Peters SP
    Curr Opin Pharmacol; 2010 Jun; 10(3):246-53. PubMed ID: 20452285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?
    Sears MR
    Thorax; 2013 Feb; 68(2):195-8. PubMed ID: 22858928
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-acting β₂ agonists for asthma: a clinical paradox.
    Williams D
    Consult Pharm; 2010 Nov; 25(11):756-9. PubMed ID: 21138824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in physicians' self-reported knowledge of, attitudes toward, and responses to the black box warning on long-acting beta-agonists.
    Karpel JP; Peters JI; Szema AM; Smith B; Anderson PJ
    Ann Allergy Asthma Immunol; 2009 Oct; 103(4):304-10. PubMed ID: 19852194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma].
    Kardos P; Berdel D; Buhl R; Criée CP; Freihorst J; Gillissen A; Karg O; Pfeifer M; Magnussen H; Rabe KF; Teschler H; Vogelmeier C; Welte T; Wettengel R; Worth H
    Pneumologie; 2010 Jun; 64(6):333-5. PubMed ID: 20533125
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of long-acting beta2-agonists in the treatment of asthma.
    Cazzola M; Matera MG
    Ther Adv Respir Dis; 2007 Oct; 1(1):35-46. PubMed ID: 19124346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting beta-agonists in asthma.
    Agarwal A
    N Engl J Med; 2009 Jul; 361(2):208; author reply 209. PubMed ID: 19587350
    [No Abstract]   [Full Text] [Related]  

  • 14. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination.
    Angus R; Reagon R; Cheesbrough A
    Int J Clin Pract; 2005 Feb; 59(2):156-62. PubMed ID: 15854190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating safety of long-acting beta agonists (LABAs) in patients with asthma.
    Bian B; Kelton CM; Wigle PR; Guo JJ
    Curr Drug Saf; 2010 Jul; 5(3):245-50. PubMed ID: 20210730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?
    Lemanske RF; Busse WW
    J Allergy Clin Immunol; 2010 Sep; 126(3):449-52. PubMed ID: 20692690
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of beta agonists.
    Donohue JF
    Respir Care; 2008 May; 53(5):618-22; discussion 623-4. PubMed ID: 18426615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled beta 2-adrenergic agonists in asthma: the evolving dilemma.
    Hui KP
    Singapore Med J; 1994 Jun; 35(3):237-9. PubMed ID: 7997893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication.
    Hartung DM; Middleton L; Markwardt S; Williamson K; Ketchum K
    Clin Ther; 2015 Jan; 37(1):114-123.e1. PubMed ID: 25465946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.